PRPH vs. XLO, ATRA, SCYX, DYAI, FBLG, FBRX, PRLD, SRZN, MDCX, and ELYM
Should you be buying ProPhase Labs stock or one of its competitors? The main competitors of ProPhase Labs include Xilio Therapeutics (XLO), Atara Biotherapeutics (ATRA), SCYNEXIS (SCYX), Dyadic International (DYAI), FibroBiologics (FBLG), Forte Biosciences (FBRX), Prelude Therapeutics (PRLD), Surrozen (SRZN), Medicus Pharma (MDCX), and Eliem Therapeutics (ELYM). These companies are all part of the "pharmaceutical products" industry.
ProPhase Labs vs.
ProPhase Labs (NASDAQ:PRPH) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, community ranking, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.
In the previous week, ProPhase Labs had 1 more articles in the media than Xilio Therapeutics. MarketBeat recorded 4 mentions for ProPhase Labs and 3 mentions for Xilio Therapeutics. ProPhase Labs' average media sentiment score of 0.96 beat Xilio Therapeutics' score of 0.72 indicating that ProPhase Labs is being referred to more favorably in the media.
9.4% of ProPhase Labs shares are held by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are held by institutional investors. 20.7% of ProPhase Labs shares are held by insiders. Comparatively, 5.2% of Xilio Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Xilio Therapeutics has a net margin of 0.00% compared to ProPhase Labs' net margin of -217.64%. ProPhase Labs' return on equity of -62.92% beat Xilio Therapeutics' return on equity.
Xilio Therapeutics has a consensus price target of $4.00, suggesting a potential upside of 436.19%. Given Xilio Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Xilio Therapeutics is more favorable than ProPhase Labs.
ProPhase Labs received 102 more outperform votes than Xilio Therapeutics when rated by MarketBeat users. However, 75.00% of users gave Xilio Therapeutics an outperform vote while only 48.93% of users gave ProPhase Labs an outperform vote.
ProPhase Labs has a beta of -0.53, suggesting that its stock price is 153% less volatile than the S&P 500. Comparatively, Xilio Therapeutics has a beta of -0.38, suggesting that its stock price is 138% less volatile than the S&P 500.
ProPhase Labs has higher revenue and earnings than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.
Summary
ProPhase Labs beats Xilio Therapeutics on 10 of the 18 factors compared between the two stocks.
Get ProPhase Labs News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRPH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ProPhase Labs Competitors List
Related Companies and Tools
This page (NASDAQ:PRPH) was last updated on 3/29/2025 by MarketBeat.com Staff
Buy PRPH Stock Free PRPH Stock Alerts